Loading
A phase 1 trial of FX-909 run by Flare Therapeutics Inc., active, not recruiting.
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma is a phase 1 interventional study registered as NCT05929235 by Flare Therapeutics Inc., with 120 participants planned, started 2023-08-24, primary completion expected 2027-10-30. Conditions recorded: Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label. Interventions recorded: FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab).
Shares Flare Therapeutics and the tag pipeline.
Shares Flare Therapeutics and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/